Avident Solutions for Pharma
Closing the gap between clinical trial efficacy and real-world outcomes — through proven, patient-centered adherence technology.
The Nonadherence Problem for Pharma
Pharmaceutical manufacturers invest billions developing oncology therapies that demonstrate strong efficacy in controlled trials. But in the real world, nonadherence systematically erodes those results — undermining ROI, distorting outcomes data, and costing the industry hundreds of billions in unrealized revenue every year. For oral oncology agents, adherence rates range from as low as 16% to 100% depending on drug, cancer type, and patient population. Many patients never sustain the exposure levels required for full therapeutic effect. The result is disease progression, reduced survival, and a widening gap between what a therapy can do and what it actually delivers in practice.
Why Nonadherence Is a Pharma Priority
- An estimated $637 billion in global pharma revenue is lost annually to medication nonadherence — approximately $250 billion in the U.S. alone
- Real-world adherence to oral oncology agents frequently falls below the 80% threshold needed for optimal therapeutic effect, leading to suboptimal drug exposure
- Nonadherence distorts real-world effectiveness data, undermining outcomes-based agreements and value-based contracts with payers
- Patients who discontinue early never realize the survival benefit your therapy was designed to deliver — and their poor outcomes can be attributed to the drug rather than adherence failure
- Unmanaged side effects are a leading driver of dose reduction and early discontinuation — a modifiable problem with the right digital support
- Poor adherence increases downstream healthcare utilization, complicating total cost-of-care narratives in payer negotiations
How MyNavigator Supports Pharma Partners
Avident Health's MyNavigator Platform (MNP) is a HIPAA-compliant digital adjuvant designed to address the known drivers of nonadherence in oncology — not just remind patients to take their medication. MNP works alongside your therapy, supporting patients and their caregivers from initiation through the full course of treatment, while generating the real-world evidence pharma partners need.
Real-World Evidence and Adherence Data
MyNavigator generates structured, longitudinal data on adherence patterns, symptom burden, patient-reported outcomes, and care utilization. For pharma partners, this supports HEOR efforts, label expansion, and outcomes-based contracting. Reports are customizable to align with your evidence generation priorities.
Proactive Symptom Monitoring to Protect On-Therapy Time
Unmanaged side effects are a leading driver of dose reduction, treatment interruption, and early discontinuation. MNP proactively monitors symptoms aligned to each regimen's tolerability profile and triages positive responses to the clinical team before problems escalate — keeping patients on therapy longer and protecting drug exposure.
Integrated Informal Caregiver (ICC) Engagement
MNP uniquely integrates informal cancer caregivers as active participants in the care team. Engaged caregivers improve symptom reporting accuracy, medication adherence, and uptake of supportive services — particularly impactful for oral therapies taken at home, where caregiver involvement is a documented positive driver of adherence.
AI-Enabled, Literacy-Adaptive Patient Education
Confusion about dosing schedules, side effect management, and treatment rationale is a modifiable cause of nonadherence. MNP's AI chatbot provides nationally guideline-aligned content adapted to each patient's health literacy level in paired audio-video format. Patients who understand their therapy are more likely to stay with it.
Patient Support Program Enhancement
MNP extends and amplifies existing patient support programs with a digital engagement layer that maintains consistent touchpoints between field team visits and hub interactions. It reduces administrative burden on support staff while increasing the frequency and quality of patient contact — without proportionally increasing cost.
Risk Stratification and Early Intervention
MNP incorporates known predictors of nonadherence — including recent hospitalization, symptom escalation, financial stress signals, and engagement drop-off — to identify at-risk patients before they discontinue. Targeted outreach at the right moment prevents the treatment interruptions that are hardest to reverse.
Protecting Real-World Performance of Oncology Therapies
Nonadherence is not a downstream patient issue—it is a direct, controllable business risk for oncology manufacturers.
When patients discontinue oral therapy early or maintain subtherapeutic exposure, the impact is immediate and measurable:
- Real-world effectiveness erodes relative to trial outcomes, weakening the value story in payer negotiations and outcomes-based contracts.
- Safety and tolerability appear worse than they are, because unmanaged side effects and poor expectations—not the molecule—drive interruptions and discontinuations.
- High-need patients never realize full benefit, undermining both clinical impact and the long-term commercial potential of the brand.
Across more than 100 studies, meta-analyses show that addressing key adherence drivers can raise adherence from ~60% to 85%+—yielding 20–40% improvements in survival and recurrence outcomes. That is the scale of impact available when adherence is treated as a core clinical and commercial imperative, not just a patient education task.
MyNavigator: A Validated, Evidence-Based Platform
Avident Health’s MyNavigator Platform has been evaluated in peer-reviewed research and presented at ASCO, giving pharma partners a credible, evidence-based solution rather than an unproven add-on.
Ongoing initiatives with organizations such as MedStar Health, Wichita Urology, Unite for Her, and Pfizer Advanced Solutions are generating real-world evidence across:
- Breast cancer
- Advanced prostate cancer
- Additional solid and hematologic oncology indications
Current research focuses on questions that map directly to pharma’s strategic priorities:
- Does automated proactive symptom monitoring improve adherence to protocol and persistence on therapy?
- Does including informal caregivers improve the accuracy and timeliness of symptom reporting?
- Can AI-enabled education and triage reduce call center volume while improving patient experience and safety?
These data streams support patient support program optimization, label and HEOR narratives, and real-world evidence strategies across the lifecycle.
Partnership Model for Pharma
Avident Health partners with oncology manufacturers to design adherence support solutions that are:
- Therapy-specific – Calibrated to the tolerability profile, dosing regimen, and risk profile of each product.
- Population-aware – Tailored to the needs, barriers, and digital literacy of defined patient segments.
- Evidence-driven – Structured to generate real-world outcomes, utilization, and experience data aligned with your evidence plan.
The MyNavigator Platform:
- Integrates seamlessly with existing patient support programs, hubs, and nurse educator teams.
- Can be deployed across multiple sites and cancer centers, supporting consistent execution at scale.
- Creates a closed loop between patients, caregivers, clinical teams, and manufacturer support resources.
Next Step: Explore a Partnership
By partnering with Avident Health, manufacturers can:
- Protect and enhance the real-world effectiveness of their therapies
- Support patients through the full intended course of treatment
- Generate robust outcomes data that demonstrates the value their therapy delivers to patients, providers, and payers
To schedule a demonstration or discuss a partnership, click below.